DURHAM, N.C., April 7, 2026
Fortrea has launched its advanced AI-powered platform, Fortrea Intelligent Technology™ (FIT), aimed at transforming clinical trial operations through enhanced data integration, automation, and real-time decision-making across the drug development lifecycle. The announcement highlights a major step forward in digital innovation within clinical research, enabling sponsors and investigator sites to improve trial efficiency, quality, and predictability.
AI-Powered FIT Platform Enhances Trial Efficiency and Integration
Fortrea Intelligent Technology™ introduces a comprehensive, AI-driven suite of solutions designed to streamline clinical trial workflows and improve operational productivity. Built on the company’s established Xcellerate® platform, FIT integrates fragmented clinical systems into a unified ecosystem, delivering near-real-time, role-based insights for faster and more accurate decision-making.
The platform is structured around three key pillars—Lifecycle, Foresight, and Companion—each addressing specific challenges in trial execution. The Lifecycle component automates trial progression, from study startup to final documentation, ensuring smoother and faster execution. The Foresight pillar leverages advanced analytics and AI to convert complex datasets into actionable intelligence, enabling proactive risk identification and mitigation. Meanwhile, the Companion tools support study teams with persona-driven solutions, improving collaboration and productivity across global clinical operations.
These capabilities reflect the increasing importance of AI-driven transformation in clinical trials, where speed, data accuracy, and operational efficiency are critical to successful outcomes.
Advertisement
Strengthening GCP Compliance and Data Integrity
A central advantage of FIT is its ability to enhance data integrity and support Good Clinical Practice (GCP) compliance, which are fundamental to modern clinical research. By incorporating machine learning and predictive analytics, the platform can identify patterns, generate insights, and automate key workflows, reducing manual effort and minimizing the risk of errors.
The enhanced Xcellerate® platform enables risk-based quality management (RBQM), central monitoring, and oversight, ensuring that trials meet regulatory expectations while maintaining high-quality standards. This aligns with global regulatory trends emphasizing risk-based monitoring, real-time oversight, and improved transparency in clinical trials.
Additionally, the platform’s ability to provide integrated data visibility across sponsors, sites, and clinical teams improves communication and coordination, supporting more efficient trial management and stronger regulatory readiness.
Accelerating Drug Development with Intelligent Technology
Fortrea’s FIT platform is designed to support biopharmaceutical, biotechnology, and medical device development programs, making it a versatile solution across the life sciences sector. By enabling automation, predictive insights, and seamless data integration, the platform addresses longstanding inefficiencies in clinical trials, helping reduce timelines and costs while improving study outcomes.
Importantly, the platform incorporates ethical and responsible AI practices, ensuring that technology complements human expertise rather than replacing it. This allows clinical teams to focus on critical decision-making and patient-centric outcomes, while routine processes are managed by intelligent systems.
As the industry moves toward digitally enabled clinical research, solutions like FIT are expected to play a key role in accelerating the development and delivery of life-changing therapies to patients worldwide.
Fortrea’s introduction of Fortrea Intelligent Technology™ marks a significant advancement in clinical trial innovation, combining AI, real-time data integration, and risk-based monitoring to improve efficiency, quality, and compliance. With strong alignment to GCP principles and evolving regulatory expectations, FIT positions itself as a transformative solution for modern clinical research.
Source: Fortrea press release
